Literature DB >> 33925471

Mass Spectrometry-Based Lipidomics Reveals Differential Changes in the Accumulated Lipid Classes in Chronic Kidney Disease.

Lukasz Marczak1, Jakub Idkowiak1,2, Joanna Tracz3, Maciej Stobiecki1, Bartłomiej Perek4, Katarzyna Kostka-Jeziorny5, Andrzej Tykarski5, Maria Wanic-Kossowska6, Marcin Borowski7, Marcin Osuch8, Dorota Formanowicz9, Magdalena Luczak3.   

Abstract

Chronic kidney disease (CKD) is characterized by the progressive loss of functional nephrons. Although cardiovascular disease (CVD) complications and atherosclerosis are the leading causes of morbidity and mortality in CKD, the mechanism by which the progression of CVD accelerates remains unclear. To reveal the molecular mechanisms associated with atherosclerosis linked to CKD, we applied a shotgun lipidomics approach fortified with standard laboratory analytical methods and gas chromatography-mass spectrometry technique on selected lipid components and precursors to analyze the plasma lipidome in CKD and classical CVD patients. The MS-based lipidome profiling revealed the upregulation of triacylglycerols in CKD and downregulation of cholesterol/cholesteryl esters, sphingomyelins, phosphatidylcholines, phosphatidylethanolamines and ceramides as compared to CVD group and controls. We have further observed a decreased abundance of seven fatty acids in CKD with strong inter-correlation. In contrast, the level of glycerol was elevated in CKD in comparison to all analyzed groups. Our results revealed the putative existence of a functional causative link-the low cholesterol level correlated with lower estimated glomerular filtration rate and kidney dysfunction that supports the postulated "reverse epidemiology" theory and suggest that the lipidomic background of atherosclerosis-related to CKD is unique and might be associated with other cellular factors, i.e., inflammation.

Entities:  

Keywords:  cardiovascular disease; chronic kidney disease; lipid profiling; lipidomics; mass spectrometry

Year:  2021        PMID: 33925471     DOI: 10.3390/metabo11050275

Source DB:  PubMed          Journal:  Metabolites        ISSN: 2218-1989


  54 in total

Review 1.  Lipid abnormalities in kidney disease and management strategies.

Authors:  Vishwam Pandya; Akhilesh Rao; Kunal Chaudhary
Journal:  World J Nephrol       Date:  2015-02-06

Review 2.  Chronic kidney disease as a coronary artery disease risk equivalent.

Authors:  Alexandrios Briasoulis; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

3.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.

Authors:  A S Levey; J A Beto; B E Coronado; G Eknoyan; R N Foley; B L Kasiske; M J Klag; L U Mailloux; C L Manske; K B Meyer; P S Parfrey; M A Pfeffer; N K Wenger; P W Wilson; J T Wright
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

4.  Cardiovascular and noncardiovascular mortality among patients starting dialysis.

Authors:  Dinanda J de Jager; Diana C Grootendorst; Kitty J Jager; Paul C van Dijk; Lonneke M J Tomas; David Ansell; Frederic Collart; Patrik Finne; James G Heaf; Johan De Meester; Jack F M Wetzels; Frits R Rosendaal; Friedo W Dekker
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

5.  Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis.

Authors:  Joseph Yeboah; Coleen McNamara; Xian-Cheng Jiang; Ira Tabas; David M Herrington; Gregory L Burke; Steven Shea
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-23       Impact factor: 8.311

6.  LION/web: a web-based ontology enrichment tool for lipidomic data analysis.

Authors:  Martijn R Molenaar; Aike Jeucken; Tsjerk A Wassenaar; Chris H A van de Lest; Jos F Brouwers; J Bernd Helms
Journal:  Gigascience       Date:  2019-06-01       Impact factor: 6.524

Review 7.  Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation.

Authors:  Chamberlain I Obialo; Elizabeth O Ofili; Keith C Norris
Journal:  Int J Environ Res Public Health       Date:  2018-12-04       Impact factor: 3.390

8.  Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients.

Authors:  Juergen Graessler; Dominik Schwudke; Peter E H Schwarz; Ronny Herzog; Andrej Shevchenko; Stefan R Bornstein
Journal:  PLoS One       Date:  2009-07-15       Impact factor: 3.240

9.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation.

Authors:  Jianguo Xia; Nick Psychogios; Nelson Young; David S Wishart
Journal:  Nucleic Acids Res       Date:  2009-05-08       Impact factor: 16.971

10.  The risk of atherosclerosis in patients with chronic kidney disease.

Authors:  Sylwia Olechnowicz-Tietz; Anna Gluba; Anna Paradowska; Maciej Banach; Jacek Rysz
Journal:  Int Urol Nephrol       Date:  2013-03-13       Impact factor: 2.370

View more
  2 in total

1.  The Mutual Contribution of 3-NT, IL-18, Albumin, and Phosphate Foreshadows Death of Hemodialyzed Patients in a 2-Year Follow-Up.

Authors:  Łukasz Kasprzak; Mateusz Twardawa; Piotr Formanowicz; Dorota Formanowicz
Journal:  Antioxidants (Basel)       Date:  2022-02-11

2.  Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls.

Authors:  Denise Wolrab; Robert Jirásko; Ondřej Peterka; Jakub Idkowiak; Michaela Chocholoušková; Zuzana Vaňková; Karel Hořejší; Ivana Brabcová; David Vrána; Hana Študentová; Bohuslav Melichar; Michal Holčapek
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.